{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-22-014392","form_type":"8-K","ticker":"ALT","cik":"0001326190","company_name":"Altimmune, Inc.","filed_at":"2022-09-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:55.386697+00:00","generated_at":"2026-06-23T09:39:05.900998+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Altimmune Phase 1b pemvidutide: 68.5% liver fat reduction, 4.9% weight loss at 12 weeks","bullets":["At 1.8 mg dose, relative liver fat reduction of 68.5%; 94.4% of subjects achieved ≥30% reduction.","Mean weight loss of 4.9% in non-diabetic subjects (placebo-adjusted 4.7%) at 1.8 mg dose.","55.6% of subjects at 1.8 mg achieved liver fat normalization (≤5%).","No serious or severe adverse events; 2 discontinuations due to GI intolerance.","Serum ALT declined >17 IU/L in subjects with baseline ALT ≥30 IU/L; no clinically significant ALT elevations."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-22-014392","json":"https://secwatch.observer/filing/0001558370-22-014392.json","markdown":"https://secwatch.observer/filing/0001558370-22-014392.md","text":"https://secwatch.observer/filing/0001558370-22-014392.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1326190/000155837022014392/0001558370-22-014392-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1326190/000155837022014392/alt-20220914x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T09:39:05.900998+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}